Abstract
MicroRNAs (miRNAs/miRs) are short non-coding RNAs that regulate gene expression by binding to the 3'-untranslated region of target mRNA, preventing protein translation or inducing mRNA destabilization. In the present study, the expression of miR-548c-3p was demonstrated to be markedly downregulated in clinical malignant glioma tissues and the glioma T98G cell line compared with normal human brain tissue. Transfection of miR-548c-3p inhibited cell proliferation by inducing G1 cell cycle arrest and also inhibited the migration of the T98G cells in vitro. Furthermore, a bioinformatic algorithm and a luciferase reporter assay identified proto-oncogene c-Myb (c-Myb) as a potential direct target of miR-548c-3p. Further experiments demonstrated that the inhibition of c-Myb by miR-548c-3p partially mediated the antitumor effect of miR-548c-3p. The results of the present study provide the novel insight that miR-548c-3p inhibits glioma tumorigenesis by targeting c-Myb.
Introduction
Gliomas represent the most common and aggressive primary brain tumors. Despite advancements in surgery, radiation, and chemotherapy, high-grade gliomas like glioblastoma multiforme remain largely incurable with a poor prognosis. This study investigates the role of microRNAs—short RNA molecules that act as regulatory switches—specifically focusing on why miR-548c-3p is downregulated in glioma and how its absence allows the oncogene c-Myb to drive tumor progression and invasion.
Methods
The study employed a rigorous molecular biology workflow to establish a causal link between miR-548c-3p and glioma progression:
- Expression Analysis: RT-qPCR compared miR-548c-3p levels in 11 clinical glioma samples versus normal brain tissue and across glioma cell lines (T98G, U87, U251).
- Functional Assays: miR-548c-3p was restored in T98G cells using synthetic mimics to measure impacts on proliferation (MTS assay), colony formation, and the cell cycle (Flow Cytometry).
- Migration Studies: Wound healing (scratch) and Transwell migration assays were used to evaluate cellular motility.
- Target Validation: TargetScan bioinformatics predicted c-Myb as a target, which was confirmed via a Luciferase Reporter Assay to prove physical binding.
- Rescue Experiments: siRNA-mediated knockdown of c-Myb was used to mimic miRNA effects, while c-Myb restoration was used to attempt to "rescue" the malignant phenotype.
Results
The study found that miR-548c-3p was significantly downregulated in all clinical samples and cell lines tested, suggesting its loss is a hallmark of glioma. Transfection of miR-548c-3p mimics resulted in a 25 ± 6.2% inhibition of cell proliferation by day 4 (P<0.01). In Transwell assays, the number of migrated cells dropped significantly from approximately 200 in controls to 137 in miRNA-treated cells.
Key Insights: Mechanism of Action
G1 Cell Cycle Arrest
Restoration of miR-548c-3p did not primarily induce cell death (apoptosis); instead, it induced G1 cell cycle arrest. Flow cytometry revealed that treated cells were effectively "frozen" in a non-dividing state, with 50% of treated cells in the G1 phase compared to 34% in controls.
c-Myb as the Primary Target
While miRNAs often have multiple targets, this study identifies the transcription factor c-Myb as the primary mediator of miR-548c-3p's effects. c-Myb is known to drive the expression of genes required for the G1/S phase transition. Luciferase assays confirmed direct physical interaction between the miRNA and the c-Myb 3'-UTR, and Western blot analysis confirmed a marked reduction in c-Myb protein levels following miRNA transfection.
Discussion and Future Directions
While these results identify miR-548c-3p as a potent tumor suppressor, several limitations remain. The clinical cohort of 11 patients is relatively small, and larger studies are required to correlate miRNA levels with tumor grade or patient survival. Furthermore, the study was conducted entirely in vitro; future in vivo validation using mouse xenograft models is necessary. Finally, translating these findings into therapy will require overcoming the significant challenge of delivering miRNA mimics across the blood-brain barrier.
Summary updated